Valuation: iTeos Therapeutics, Inc.

Market Cap 449M 392M 362M 334M 634M 42.79B 645M 4.33B 1.7B 21.08B 1.68B 1.65B 72.47B P/E 2023
-3.48x
P/E 2024 -2.31x
Enterprise Value -40.87M -35.75M -32.97M -30.45M -57.78M -3.9B -58.75M -394M -155M -1.92B -153M -150M -6.6B EV / Sales 2023
-10,640,152x
EV / Sales 2024 -5,970,615x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
1 year 10.08
Extreme 10.08
10.47
3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Executive Officer 59 2025-08-27
Chief Operating Officer - 2025-08-27
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2025-08-27
Date Insider Type Main position Quantity % Market Cap.
25-08-28Issuer sale

Director

27,178 0.0710%
25-08-28Issuer sale

Director

171,300 0.4476%
25-08-28Tender

Chief Executive Officer; Director

1,106,638 2.8914%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--%-1.36%-26.61% 449M
-4.14%-8.06%+58.96%+118.67% 54.63B
+1.84%-0.66%+59.82%+92.96% 54.88B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.95%+194.27% 14.2B
+8.74%+3.51%+51.91%+726.40% 15.36B
Average -0.58%-0.25%+46.72%+189.69% 24.16B
Weighted average by Cap. -0.91%-1.46%+51.17%+175.87%

Financials

2023 2024
Net sales 12.6 11.02 10.16 9.39 17.81 1.2K 18.11 121.41 47.68 591.77 47.29 46.26 2.03K 35 30.61 28.24 26.08 49.49 3.34K 50.32 337.4 132.5 1.64K 131.41 128.56 5.65K
Net income -113M -98.53M -90.88M -83.94M -159M -10.74B -162M -1.09B -426M -5.29B -423M -414M -18.19B -134M -118M -108M -100M -190M -12.82B -193M -1.3B -509M -6.32B -505M -494M -21.71B
Net Debt -526M -460M -424M -392M -744M -50.15B -756M -5.07B -1.99B -24.71B -1.97B -1.93B -84.94B -490M -428M -395M -365M -692M -46.69B -704M -4.72B -1.85B -23B -1.84B -1.8B -79.07B
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock